Type
- ARTG (494)
- Cancellation by sponsor (465)
- Australian Public Assessment Report (AusPAR) (63)
- Prescription medicine registration (41)
- Section 14, TGO91 consent (21)
- Prescription medicine decision summary (19)
- Designation or determination (9)
- Cancellation or suspension (7)
- Prescription medicine evaluation (2)
Date
- 2024 (62)
- 2023 (73)
- 2022 (61)
- 2021 (126)
- 2020 (107)
- 2019 (98)
- 2018 (98)
- 2017 (74)
- 2016 (12)
- 2015 (22)
- 2014 (23)
- 2013 (9)
- 2012 (9)
- 2011 (14)
- 2010 (29)
- 2009 (13)
- 2008 (6)
- 2007 (12)
- 2006 (8)
- 2005 (4)
- 2004 (8)
- 2003 (9)
- 2002 (13)
- 2001 (8)
- 2000 (22)
- 1999 (12)
- 1998 (12)
- 1997 (18)
- 1996 (8)
- 1995 (3)
- 1994 (33)
- 1993 (19)
- 1992 (8)
- 1991 (88)
Results for
"[search-keyword]"
Sponsor content
1121 result(s) found, displaying 41 to 50
-
Prescription medicine registrationActive ingredients: elranatamab.
-
Prescription medicine registrationActive ingredients: ritlecitinib tosylate.
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ABRYSVO recombinant respiratory syncytial virus pre-fusion F protein 120 microgram/0.5 mL bivalent vaccine powder for injection vial + diluent syringe.
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Prescription medicine decision summaryAbrysvo (recombinant respiratory syncytial virus pre-fusion F protein bivalent vaccine) was approved for the prevention of lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV) in certain patient groups.
-
Australian Public Assessment Report (AusPAR)Abrysvo is a vaccine that provides active immunisation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).